DMAC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DMAC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. DiaMedica Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $0.00 Mil. DiaMedica Therapeutics's average total debt for the quarter that ended in Mar. 2024 was $0.39 Mil. Therefore, DiaMedica Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 0.00%.
The historical data trend for DiaMedica Therapeutics's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DiaMedica Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Effective Interest Rate on Debt % | Get a 7-Day Free Trial | - | - | - | - | - |
DiaMedica Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Effective Interest Rate on Debt % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, DiaMedica Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where DiaMedica Therapeutics's Effective Interest Rate on Debt % falls into.
DiaMedica Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (A: Dec. 2022 ) | + | Total Debt (A: Dec. 2023 )) | / count ) |
= | -1 * 0 | / | ( (0.469 | + | 0.4) | / 2 ) |
= | -1 * 0 | / | 0.4345 | |||
= | 0.00 % |
where
Total Debt (A: Dec. 2022 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 0.4 | + | 0.069 |
= | 0.469 |
Total Debt (A: Dec. 2023 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 0.317 | + | 0.083 |
= | 0.4 |
DiaMedica Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (Q: Dec. 2023 ) | + | Total Debt (Q: Mar. 2024 )) | / count ) |
= | -1 * 0 | / | ( (0.4 | + | 0.38) | / 2 ) |
= | -1 * 0 | / | 0.39 | |||
= | 0.00 % |
where
Total Debt (Q: Dec. 2023 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 0.317 | + | 0.083 |
= | 0.4 |
Total Debt (Q: Mar. 2024 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 0.294 | + | 0.086 |
= | 0.38 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.
DiaMedica Therapeutics (NAS:DMAC) Effective Interest Rate on Debt % Explanation
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Thank you for viewing the detailed overview of DiaMedica Therapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.
Jan Stahlberg | 10 percent owner | C/O TRILL INVEST AB, SVEAVAGEN 17 FL 18, STOCKHOLM V7 SE 111 57 |
Scott Kellen | officer: CFO and Secretary | 3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447 |
Randall Michael Giuffre | director | 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447 |
Ab Trill | 10 percent owner | SVEAVAGEN 17, 18TH FLOOR, STOCKHOLM V7 SE-11157 |
Richard D. Pilnik | director | 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447 |
Dietrich John Pauls | director, officer: President and CEO | 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447 |
Richard Ii Jacinto | 10 percent owner | 394 SADDLE BACK TRAIL, FRANKLIN LAKES NJ 07417 |
David J. Wambeke | officer: Chief Business Officer | 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305 |
Private Ab Tomeqt | 10 percent owner | C/O KINKON AB, BIBLIOTEKSGATAN 25, STOCKHOLM V8 11435 |
Koch Thomas Von | 10 percent owner | TOMENTERPRISE AB, BOX 5322, STOCKHOLM V7 102 47 |
Ab Tomenterprise | 10 percent owner | C/O EQT PARTNERS AB, BOX 16509, STOCKHOLM V7 103 27 |
Charles Pauling Semba | director | TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447 |
Richard Kuntz | director | MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432 |
Tanya Lewis | director | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459 |
Julie Vanorsdel Daves | officer: SVP Clinical Development Oper. | 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305 |
From GuruFocus
By Business Wire Business Wire • 10-31-2022
By GuruFocus Research • 11-14-2023
By Business Wire • 11-06-2023
By Business Wire Business Wire • 06-21-2023
By Business Wire Business Wire • 05-25-2022
By Business Wire • 11-09-2023
By Business Wire Business Wire • 05-08-2023
By Business Wire • 06-26-2023
By Business Wire Business Wire • 08-04-2022
By Business Wire Business Wire • 07-06-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.